SEARCH

SEARCH BY CITATION

References

  • Abbasi AA, Prasad AS, Ortega J, Congco E & Oberleas D. (1976) Gonadal function abnormalities in sickle cell anemia. Studies in adult male patients. Ann Intern Med 85, 601605.
  • Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM et al. (2004) Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 89, 59205926.
  • Asnani MR, Lipps GE & Reid ME. (2009) Utility of WHOQOL-BREF in measuring quality of life in sickle cell disease. Health Qual Life Outcomes 7, 75.
  • Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS et al. (2010) Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 95, 25362559.
  • Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E et al. (2011) Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 96, 24302439.
  • Bivalacqua TJ, Liu T, Musicki B, Champion HC & Burnett AL. (2007) Endothelial nitric oxide synthase keeps erection regulatory function balance in the penis. Eur Urol 51, 17321740.
  • Bivalacqua TJ, Musicki B, Kutlu O & Burnett AL. (2012) New insights into the pathophysiology of sickle cell disease-associated priapism. J Sex Med 9, 7987.
  • Burnett AL. (2006) Nitric oxide in the penis–science and therapeutic implications from erectile dysfunction to priapism. J Sex Med 3, 578582.
  • Burnett AL & Bivalacqua TJ. (2007) Priapism: current principles and practice. Urol Clin North Am 34, 631642, viii.
  • Burnett AL, Musicki B, Jin L & Bivalacqua TJ. (2006) Nitric oxide/redox-based signalling as a therapeutic target for penile disorders. Expert Opin Ther Targets 10, 445457.
  • Burnett AL, Kan-Dobrosky N & Miller MG. (2013) Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. J Sex Med doi: 10.1111/jsm.12059. [Epub ahead of print]
  • Champion HC, Bivalacqua TJ, Takimoto E, Kass DA & Burnett AL. (2005) Phosphodiesterase-5a dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA 102, 16611666.
  • Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A et al. (2011) Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 165, 687701.
  • Dada OA & Nduka EU. (1980) Endocrine function and haemoglobinopathies: relation between the sickle cell gene and circulating plasma levels of testosterone, luteinising hormone (LH) and follicle stimulating hormone (FSH) in adult males. Clin Chim Acta 105, 269273.
  • Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD et al. (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87, 589598.
  • Feneley MR & Carruthers M. (2012) Is testosterone treatment good for the prostate? Study of safety during long-term treatment. J Sex Med doi: 10.1111/j.1743-6109.2012.02808.x. [Epub ahead of print]
  • Fowler JE Jr & Whitmore WF Jr. (1982) Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer 49, 13731377.
  • Jan Z, Pfeifer M & Zorn B. (2012) Reversible testosterone- induced azoospermia in a 45 year old man attending an infertility outpatient clinic. Andologia 44, 823825.
  • Kato GJ, McGowan V, Machado RF, Little JA, Taylor J 6th, Morris CR et al. (2006) Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 107, 22792285.
  • Key LL, Myers MC, Kroovand RL & Kelly WS. (1989) Priapism following testosterone therapy for delayed puberty. Am J Dis Child 143, 10011002.
  • Lundh B & Gardner FH. (1970) The haematological response to androgens in sickle cell anaemia. Scand J Haematol 7, 389397.
  • Mackey MA, Conway AJ & Handelsman DJ. (1995) Tolerability of intramuscular injections of testosterone ester in oil vehicle. Hum Reprod 10, 862865.
  • Mantadakis E, Cavender JD, Rogers ZR, Ewalt DH & Buchanan GR. (1999) Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol 21, 518522.
  • Meusburger SM & Keast JR. (2001) Testosterone and nerve growth factor have distinct but interacting effects on structure and neurotransmitter expression of adult pelvic ganglion cells in vitro. Neuroscience 108, 331340.
  • Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JP, Lue TF et al. (2003) American urological association guideline on the management of priapism. J Urol 170, 13181324.
  • Moon du G, Park MG, Lee SW, Park K, Park JK, Kim SW et al. (2010) The efficacy and safety of testosterone undecanoate (Nebido®) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med 7, 22532260.
  • Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M et al. (2004) Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 145, 22532263.
  • Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D et al. (2000) Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 49, 12391242.
  • Morrison BF & Burnett AL. (2012) Stuttering priapism: insights into pathogenesis and management. Curr Urol Rep 13, 268276.
  • Olambiwonnu NO, Penny R & Frasier SD. (1975) Sexual maturation in subjects with sickle cell anemia: studies of serum gonadotropin concentration, height, weight, and skeletal age. J Pediatr 87, 459464.
  • Osegbe DN & Akinyanju OO. (1981) Fertility in males with sickle cell disease. Lancet 2, 275276.
  • Osegbe DN & Akinyanju OO. (1987) Testicular dysfunction in men with sickle cell disease. Postgrad Med J 63, 9598.
  • Parshad O, Stevens MC, Preece MA, Thomas PW & Serjeant GR. (1994) The mechanism of low testosterone levels in homozygous sickle-cell disease. West Indian Med J 43, 1214.
  • Pierorazio PM, Bivalacqua TJ & Burnett AL. (2011) Daily phosphodiesterase type 5 inhibitor therapy as rescue for recurrent ischemic priapism after failed androgen ablation. J Androl 32, 371374.
  • Prasad AS, Schoomaker EB, Ortega J, Brewer GJ, Oberleas D & Oelshlegel FJ Jr. (1975) Zinc deficiency in sickle cell disease. Clin Chem 21, 582587.
  • Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J & Mishra A. (1997) The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49, 822830.
  • Saad F & Gooren LJ. (2011) The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes 2011, doi: 10.1155/2011/471584
  • Saad F, Grahl AS, Aversa A, Yassin AA, Kadioglu A, Moncada I et al. (2007) Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction. BJU Int 99, 988992.
  • Serjeant GR & Serjeant BE. (2001) Basic concepts. In: Sickle Cell Disease, 3rd edn (eds GR Serjeant & BE Serjeant), pp. 315. Oxford University Press, Oxford.
  • Singhal A, Gabay L & Serjeant GR. (1995) Testosterone deficiency and extreme retardation of puberty in homozygous sickle-cell disease. West Indian Med J 44, 2023.
  • Slayton W, Kedar A & Schatz D. (1995) Testosterone induced priapism in two adolescents with sickle cell disease. J Pediatr Endocrinol Metab 8, 199203.
  • Traish A & Kim N. (2005) The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med 2, 759770.
  • Wang C, Harnett M, Dobs A & Swerdloff R. (2010) Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84 week phase III clinical trial. J Androl 31, 457465.
  • World Health Organization Quality of Life Group (1998) Development of the world health organization WHOQOL-BREF quality of life assessment. The WHOQOL group. Psychol Med 28, 551558.
  • Yassin AA & Saad F. (2006) Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido). World J Urol 24, 639644.
  • Zargooshi J. (2000) Priapism as a complication of high dose testosterone therapy in a man with hypogonadism. J Urol 163, 907.
  • Zelissen PM & Stricker BH. (1988) Severe priapism as a complication of testosterone substitution therapy. Am J Med 85, 273274.
  • Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H & Maggi M. (2012) IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med. Epub.
  • Zvara P, Sioufi R, Schipper HM, Begin LR & Brock GB. (1995) Nitric oxide mediated erectile activity is a testosterone dependent event: a rat erection model. Int J Impot Res 7, 209219.